MA34156B1 - Procédédepréparationde 4-{4-[({[4-chloro-3-(trifluorométhyl)-phényl]amino}carbonyl)amino]-3-fluorophénoxy}-n-éthylpyridine - Google Patents

Procédédepréparationde 4-{4-[({[4-chloro-3-(trifluorométhyl)-phényl]amino}carbonyl)amino]-3-fluorophénoxy}-n-éthylpyridine

Info

Publication number
MA34156B1
MA34156B1 MA35304A MA35304A MA34156B1 MA 34156 B1 MA34156 B1 MA 34156B1 MA 35304 A MA35304 A MA 35304A MA 35304 A MA35304 A MA 35304A MA 34156 B1 MA34156 B1 MA 34156B1
Authority
MA
Morocco
Prior art keywords
amino
trifluoromethyl
carbonyl
chloro
phenyl
Prior art date
Application number
MA35304A
Other languages
English (en)
Inventor
Juergen Stiehl
Werner Heilmann
Michael Loegers
Joachim Rehse
Michael Gottfried
Saskia Wichmann
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44070712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34156(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA34156B1 publication Critical patent/MA34156B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Containers And Plastic Fillers For Packaging (AREA)

Abstract

La présente invention concerne un procédé de préparation de 4-{4-[({[4-chloro-3-(trifluorométhyl)-phényl]amino}carbonyl)amino]
MA35304A 2010-04-15 2011-04-08 Procédédepréparationde 4-{4-[({[4-chloro-3-(trifluorométhyl)-phényl]amino}carbonyl)amino]-3-fluorophénoxy}-n-éthylpyridine MA34156B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10004022 2010-04-15
PCT/EP2011/055508 WO2011128261A1 (fr) 2010-04-15 2011-04-08 Procédé de préparation de 4-{4-[({[4-chloro-3-(trifluorométhyl)-phényl]amino}carbonyl)amino]-3-fluorophénoxy}-n-méthylpyridine-2-carboxamide, ses sels et son monohydrate

Publications (1)

Publication Number Publication Date
MA34156B1 true MA34156B1 (fr) 2013-04-03

Family

ID=44070712

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35304A MA34156B1 (fr) 2010-04-15 2011-04-08 Procédédepréparationde 4-{4-[({[4-chloro-3-(trifluorométhyl)-phényl]amino}carbonyl)amino]-3-fluorophénoxy}-n-éthylpyridine

Country Status (40)

Country Link
US (5) US8748622B2 (fr)
EP (1) EP2558448B1 (fr)
JP (1) JP5934182B2 (fr)
KR (2) KR20170129276A (fr)
CN (2) CN103980191A (fr)
AR (2) AR081060A1 (fr)
AU (1) AU2011240113B2 (fr)
BR (1) BR112012026117B1 (fr)
CA (1) CA2796238C (fr)
CL (1) CL2012002840A1 (fr)
CO (1) CO6630136A2 (fr)
CR (1) CR20120526A (fr)
CU (2) CU24123B1 (fr)
DK (1) DK2558448T3 (fr)
DO (2) DOP2012000268A (fr)
EC (1) ECSP12012234A (fr)
ES (1) ES2542610T3 (fr)
GT (1) GT201200280A (fr)
HK (1) HK1200831A1 (fr)
HR (1) HRP20150885T1 (fr)
HU (1) HUE026821T2 (fr)
IL (2) IL222348B (fr)
JO (1) JO3158B1 (fr)
MA (1) MA34156B1 (fr)
MX (1) MX2012011734A (fr)
MY (2) MY177066A (fr)
NZ (1) NZ602997A (fr)
PE (2) PE20130181A1 (fr)
PH (1) PH12012502060A1 (fr)
PL (1) PL2558448T3 (fr)
PT (1) PT2558448E (fr)
RS (1) RS54219B1 (fr)
RU (1) RU2581585C2 (fr)
SG (2) SG10201501221UA (fr)
SI (1) SI2558448T1 (fr)
TN (1) TN2012000492A1 (fr)
TW (2) TWI539951B (fr)
UA (1) UA110613C2 (fr)
UY (2) UY33290A (fr)
WO (1) WO2011128261A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1797038T3 (da) * 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
ATE482693T1 (de) 2005-03-07 2010-10-15 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
AR092439A1 (es) 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
EP2900269B1 (fr) 2012-09-25 2018-08-01 Bayer Pharma Aktiengesellschaft Combinaison de régorafénib et d'acide acétylsalicylique destinée au traitement du cancer colorectal
CN104250227A (zh) * 2013-06-29 2014-12-31 广东东阳光药业有限公司 瑞戈非尼新晶型及其制备方法
WO2015049698A2 (fr) * 2013-10-04 2015-04-09 Hetero Research Foundation Procédé pour le régorafénib
CN105218439B (zh) * 2014-06-06 2018-11-20 连云港润众制药有限公司 一种瑞格非尼的晶体及其制备方法
WO2016005874A1 (fr) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Procédé pour la préparation du régorafénib et ses formes cristallines
CN104557689B (zh) * 2015-01-26 2016-06-29 重庆两江药物研发中心有限公司 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法
CN104592105B (zh) * 2015-02-10 2017-01-18 杭州朱养心药业有限公司 瑞戈非尼及其制法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
SG11201806116SA (en) * 2016-01-18 2018-08-30 Natco Pharma Ltd An improved process for the preparation of regorafenib
CN107118153A (zh) * 2016-02-25 2017-09-01 石药集团中奇制药技术（石家庄）有限公司 一种瑞戈非尼一水合物晶型及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CA3244313A1 (en) 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN109438337B (zh) * 2018-11-27 2019-08-09 广东安诺药业股份有限公司 一种瑞戈非尼中间体的制备工艺
CN109438336B (zh) * 2018-11-27 2019-11-22 广东安诺药业股份有限公司 一种瑞戈非尼水合物的制备方法
EP3861989A1 (fr) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Composition pharmaceutique contenant du régorafénib et un agent de stabilisation
WO2021160708A1 (fr) 2020-02-14 2021-08-19 Bayer Aktiengesellschaft Combinaison de régorafenib et de msln-ttc pour traiter le cancer
CN114315710B (zh) * 2022-01-07 2024-04-26 江苏豪森药业集团有限公司 一种制备或纯化瑞戈非尼的方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080269265A1 (en) 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ME00275B (fr) 1999-01-13 2011-02-10 Bayer Corp DIPHENYLUREES A SUBSTITUANTS ω-CARBOXYARYLES, INHIBITRICES DE KINASE RAF
EP1158985B1 (fr) 1999-01-13 2011-12-28 Bayer HealthCare LLC DIPHENYLE UREES A SUBSTITUTION OMEGA-CARBOXY ARYLE EN TANT QU'INHIBITEURS DE LA KINASE p38
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2003047579A1 (fr) 2001-12-03 2003-06-12 Bayer Pharmaceuticals Corporation Composes de type uree aryle combines a d'autres agents cytostatiques ou cytotoxiques et servant a traiter des cancers humains
WO2003068229A1 (fr) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation N-oxydes de pyridine, de quinoline, et d'isoquinoline en tant qu'inhibiteurs de kinase
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (fr) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-urees presentant une activite d'inhibition des kinases
EP1663978B1 (fr) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
EP2295426A1 (fr) 2004-04-30 2011-03-16 Bayer HealthCare, LLC Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
ATE395905T1 (de) 2004-08-27 2008-06-15 Bayer Pharmaceuticals Corp Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
EP1797037B1 (fr) 2004-09-29 2014-12-17 Bayer HealthCare LLC Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
DK1797038T3 (da) 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
ATE482693T1 (de) 2005-03-07 2010-10-15 Bayer Schering Pharma Ag Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
US20090215835A1 (en) 2005-10-31 2009-08-27 Scott Wilhelm Treatment of cancer with sorafenib
JP2009515978A (ja) 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Ｋｉｔ阻害剤に対する獲得耐性を伴う癌の治療
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100063112A1 (en) * 2006-11-09 2010-03-11 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
EP2089363A1 (fr) * 2006-11-14 2009-08-19 Bayer Schering Pharma Aktiengesellschaft Polymorphe ii de 4-[4-({[4-chloro-3-(trifluorométhyl)phényl]carbamoyl}amino)-3-fluorophénoxy]-n-méthylpyridine-2-carboxamide
AU2007336873A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4-[({3-tert-Butyl-1-[3-(hydroxymethyl) phenyl]-1H-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -N-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
JP2010516692A (ja) 2007-01-19 2010-05-20 バイエル・ヘルスケア・エルエルシー 化学療法剤に対し抵抗性を有する癌の処置
CA2675980C (fr) 2007-01-19 2016-06-21 Bayer Healthcare Llc Utilisation de dast dans le traitement des cancers a resistance acquise a des inhibiteurs de kit
EP2156834A1 (fr) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Compositions pharmaceutiques ophtalmiques comprenant du Sorafenib pour le traitement de pathologies néoangiogéniques de l'ýil
JP5439494B2 (ja) 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
AU2010247397B2 (en) 2009-05-15 2012-07-12 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CA2805874A1 (fr) 2010-07-19 2012-01-26 Bayer Healthcare Llc Associations medicamenteuses contenant une omega-carboxyaryl diphenyluree fluorosubstituee utilisees pour le traitement et la prevention de maladies et d'affections
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
CN103764118A (zh) 2011-06-28 2014-04-30 拜尔健康护理有限责任公司 含有索拉非尼的局部眼用药用组合物
KR20140048218A (ko) 2011-06-28 2014-04-23 바이엘 헬스케어 엘엘씨 레고라페닙을 함유하는 국소 안과용 약학 조성물
US8841500B2 (en) 2011-11-08 2014-09-23 Chevron U.S.A. Inc. Preparation of alkyl aromatic compounds
JP2014032346A (ja) 2012-08-06 2014-02-20 Japan Display Inc 液晶表示パネル
AR092439A1 (es) 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib

Also Published As

Publication number Publication date
US10822305B2 (en) 2020-11-03
KR101800041B1 (ko) 2017-11-21
AR116395A2 (es) 2021-05-05
CA2796238C (fr) 2019-12-31
WO2011128261A1 (fr) 2011-10-20
TN2012000492A1 (en) 2014-04-01
HK1200831A1 (en) 2015-08-14
PH12012502060A1 (en) 2013-02-04
NZ602997A (en) 2014-10-31
ECSP12012234A (es) 2012-11-30
KR20170129276A (ko) 2017-11-24
BR112012026117A8 (pt) 2017-12-19
BR112012026117B1 (pt) 2022-08-30
IL253119B (en) 2018-03-29
IL253119A0 (en) 2017-08-31
CL2012002840A1 (es) 2013-01-18
PL2558448T3 (pl) 2015-10-30
AR081060A1 (es) 2012-06-06
PT2558448E (pt) 2015-09-01
TW201204356A (en) 2012-02-01
US8748622B2 (en) 2014-06-10
PE20160838A1 (es) 2016-09-24
BR112012026117A2 (pt) 2015-09-08
DOP2016000285A (es) 2016-11-30
ES2542610T3 (es) 2015-08-07
CU24123B1 (es) 2015-08-27
SG10201501221UA (en) 2015-04-29
CA2796238A1 (fr) 2011-10-20
DK2558448T3 (en) 2015-08-24
GT201200280A (es) 2014-07-23
MX2012011734A (es) 2012-12-17
UY33290A (es) 2011-12-01
KR20130061670A (ko) 2013-06-11
RU2581585C2 (ru) 2016-04-20
CN103980191A (zh) 2014-08-13
US20190144391A1 (en) 2019-05-16
CN102947271A (zh) 2013-02-27
CR20120526A (es) 2013-03-11
TWI539951B (zh) 2016-07-01
CN102947271B (zh) 2016-11-09
RU2012148386A (ru) 2014-05-20
CU20140060A7 (es) 2014-10-02
CO6630136A2 (es) 2013-03-01
AU2011240113B2 (en) 2014-12-18
TWI475992B (zh) 2015-03-11
UA110613C2 (uk) 2016-01-25
IL222348A0 (en) 2012-12-31
SG184172A1 (en) 2012-11-29
JP5934182B2 (ja) 2016-06-15
JO3158B1 (ar) 2017-09-20
US20130116442A1 (en) 2013-05-09
TW201509415A (zh) 2015-03-16
MY177066A (en) 2020-09-03
RS54219B1 (sr) 2015-12-31
EP2558448A1 (fr) 2013-02-20
DOP2012000268A (es) 2012-12-15
US9458107B2 (en) 2016-10-04
HUE026821T2 (en) 2016-07-28
PE20130181A1 (es) 2013-02-23
UY39590A (es) 2022-01-31
IL222348B (en) 2018-08-30
US20170057918A1 (en) 2017-03-02
MY162359A (en) 2017-06-15
US20140221661A1 (en) 2014-08-07
US20170334857A1 (en) 2017-11-23
HRP20150885T1 (hr) 2015-10-09
CU20120147A7 (es) 2013-01-30
JP2013523851A (ja) 2013-06-17
SI2558448T1 (sl) 2015-11-30
AU2011240113A1 (en) 2012-10-11
EP2558448B1 (fr) 2015-05-20

Similar Documents

Publication Publication Date Title
MA34156B1 (fr) Procédédepréparationde 4-{4-[({[4-chloro-3-(trifluorométhyl)-phényl]amino}carbonyl)amino]-3-fluorophénoxy}-n-éthylpyridine
GT201300078A (es) Proceso para la preparacion de inhibidores de pan-cdk de la formula ( i ), e intermediarios de la preparacion
EA201300388A1 (ru) Соединения замещенного бензамида
SI2609071T1 (sl) Novi postopek za pripravo intermediatov, uporabnih za izdelavo NEP inhibitorjev
CL2009000503A1 (es) Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida.
EP2590649A4 (fr) Procédé de synthèse de morphinanes substitués
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
MD20130094A2 (en) Process for the preparation of a rivaroxaban and intermediates formed in said process
NZ702935A (en) Process for making hydroxylated cyclopentylpyrimidine compounds
MY152980A (en) Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid
JOP20180012A1 (ar) عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
MY164880A (en) Process for the preparation of isoxazolyl-methoxy-nicotinic acids
EA201200498A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
CR20120630A (es) Nuevos procesos
EA201200123A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MX2013006017A (es) Separacion de enantiomeros derivados de triazina usando acido tartarico.
MX2012010443A (es) Proceso para la preparacion de 1-alquiltetrazoles 5-sustituidos.
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
EA201100230A1 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
EA201201385A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
JO3185B1 (ar) طريقة لتحضير مشتقات استر متغايرة الحلقة
MY161361A (en) Substituted phenyl compounds
CY1119348T1 (el) Διαδικασια για την παρασκευη [4,6-δις-διμεθυλαμινο-2- [4- (4-τριφθορομεθυλοβενζοϋλο-αμινο)βενζυλο]πυριμιδιν-5-υλο]οξικου οξεος
IN2011CH03419A (fr)
PH12013501279A1 (en) New process for the synthesis of agomelatine